Business context and reporting period
Hydrofarm Holdings Group, Inc. manufactures and distributes controlled-environment agriculture (CEA) equipment and supplies, primarily in the U.S. and Canada. This Form 10-K covers the fiscal year ended December 31, 2022; comparisons are with fiscal 2021. The company serves more than 2,000 wholesale accounts. It estimates about two-thirds of sales come from replenishable consumables, and approximately 75% from proprietary or preferred brands.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Net sales | $344.5 million | $479.4 million |
| Gross profit / margin | $29.3 million / 8.5% | $101.5 million / 21.2% |
| Operating loss | $281.6 million | $2.7 million |
| Net income (loss) | $(285.4) million | $13.4 million |
| Adjusted EBITDA (non-GAAP) | $(21.2) million / (6.2)% of sales | $47.1 million / 9.8% of sales |
| Cash from (used in) operations | $22.0 million | $(45.1) million |
| Cash and cash equivalents at year-end | $21.3 million | $26.6 million |
Sales fell 28.1%. Total product volume declined 29.5%; organic sales fell 46.5%, partly offset by 17.0% growth from 2021-acquired proprietary brands. Price and mix added 1.7%, while foreign exchange reduced sales by 0.3%. Management attributed the volume decline primarily to agricultural oversupply in the cannabis market.
FY 2022 included a $189.6 million goodwill impairment, reducing goodwill to zero, and a $2.6 million impairment of a note receivable. Inventory obsolescence charges were $18.5 million, primarily related to lighting products; accounts receivable allowances and write-downs were $2.9 million. Restructuring charges totaled $7.7 million, mostly inventory markdowns and facility-related costs. These items substantially affected reported results; Adjusted EBITDA is a non-GAAP measure and excludes specified items.
Cash from operations benefited from a $39.6 million net working-capital inflow, including a $57.0 million reduction in inventory. Investing cash use was $8.5 million, mainly capital expenditures; financing cash use was $20.2 million, including $15.5 million in contingent-consideration payments and $1.3 million of term-loan principal repayments.
Year-end debt was $120.7 million on the balance sheet, net of unamortized discount and financing costs; the term-loan principal was $123.75 million. The $125 million term loan has floating-rate interest and matures in 2028. The revolving facility has a $75 million commitment, no borrowings at year-end, and approximately $40 million available before the minimum fixed-charge-coverage covenant applies. The facility matures in March 2024. The company reported compliance with debt covenants at year-end. A 100-basis-point increase in rates would raise annual interest expense by approximately $1.2 million, based on year-end exposure.
Material changes, outlook and risks
- Gross margin contracted sharply as lower sales combined with inventory obsolescence, restructuring costs, and freight and labor costs that were higher relative to sales. SG&A increased 13.8%, including higher acquisition-related amortization and credit allowances, partly offset by lower acquisition and integration expenses.
- Management began a restructuring plan in the fourth quarter of 2022 to narrow the product portfolio and consolidate or relocate facilities, alongside workforce reductions. The plan removes about one-third of products and one-fifth of brands in the primary portfolio. Management expects approximately $7.0 million of annualized savings, about $1.7 million of additional charges in the first half of 2023, and completion in that half; a further restructuring phase remains possible.
- Management expects positive operating cash flow over the next 12 months and considers cash, operating cash flow, and revolver availability adequate for expected needs, while cautioning that actual cash generation and borrowing availability are uncertain. It expects typical seasonal sales patterns to return in 2023, although that pattern did not hold in 2022.
- In January 2023, the company sold its Eugene, Oregon property for $8.6 million and entered a 15-year leaseback. The filing accounts for it as a failed sale-leaseback, retaining the asset and recognizing a financial liability; proceeds are intended for permitted investments, such as capital expenditures.
- Key risks include persistent CEA and cannabis-market oversupply, customer demand and inventory valuation, floating-rate debt and the revolving facility’s 2024 maturity, refinancing and covenant constraints, long-term leases, supplier and freight disruption, and regulatory uncertainty because cannabis remains illegal under U.S. federal law. Credit-facility terms restrict direct sales to specified cannabis customers. The company also reported a January 2022 cyberattack on systems associated with the Aurora acquisition; its investigation found no evidence of spread beyond those systems or access to critical data.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also assessed controls as effective. The filing reports no known legal proceedings expected to have a material adverse effect.
Important facts for investors to verify
- Whether demand and sales stabilize, particularly given the company’s stated exposure to cannabis-related end markets and the scale of the organic-sales decline.
- Whether inventory can be sold without further markdowns, and whether the $15.7 million year-end excess-and-obsolete inventory reserve adequately reflects demand and product obsolescence.
- Whether restructuring savings are achieved on schedule and without further costs, facility disruptions, or loss of sales.
- Liquidity and refinancing: revolver availability under the borrowing base and covenant thresholds, the March 2024 revolving-facility maturity, and the ability to service floating-rate term debt.
- The effect of the Eugene sale-leaseback’s accounting and 15-year rent commitment, and how proceeds are used.
- Whether management’s positive cash-flow and 2023 seasonality expectations are realized; FY 2022 operating cash flow benefited materially from working-capital reductions.